CA3136450C - Anticorps ciblant la cd47 humaine - Google Patents

Anticorps ciblant la cd47 humaine

Info

Publication number
CA3136450C
CA3136450C CA3136450A CA3136450A CA3136450C CA 3136450 C CA3136450 C CA 3136450C CA 3136450 A CA3136450 A CA 3136450A CA 3136450 A CA3136450 A CA 3136450A CA 3136450 C CA3136450 C CA 3136450C
Authority
CA
Canada
Prior art keywords
seq
variable region
chain variable
antibody
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA3136450A
Other languages
English (en)
Other versions
CA3136450A1 (fr
Inventor
Aaron Kurtzman
Shihao Chen
Original Assignee
QLSF Biotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by QLSF Biotherapeutics Inc filed Critical QLSF Biotherapeutics Inc
Priority claimed from PCT/US2020/028851 external-priority patent/WO2020215012A1/fr
Publication of CA3136450A1 publication Critical patent/CA3136450A1/fr
Application granted granted Critical
Publication of CA3136450C publication Critical patent/CA3136450C/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Abstract

L'invention concerne des anticorps isolés qui se lient à la CD47 et la bloquent, des vecteurs comprenant une molécule d'acide nucléique codant pour une séquence d'acides aminés de la molécule de liaison, et des cellules hôtes contenant lesdits vecteurs. L'invention concerne également des procédés de préparation des anticorps, des compositions pharmaceutiques contenant les anticorps, et des méthodes d'utilisation de tels anticorps, fragments d'anticorps et dérivés et polypeptides, tels que dans le traitement de maladies, notamment le cancer.
CA3136450A 2019-04-18 2020-04-17 Anticorps ciblant la cd47 humaine Active CA3136450C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962835737P 2019-04-18 2019-04-18
US62/835,737 2019-04-18
PCT/US2020/028851 WO2020215012A1 (fr) 2019-04-18 2020-04-17 Anticorps ciblant la cd47 humaine

Publications (2)

Publication Number Publication Date
CA3136450A1 CA3136450A1 (fr) 2020-10-22
CA3136450C true CA3136450C (fr) 2025-10-07

Family

ID=

Similar Documents

Publication Publication Date Title
CN109843927B (zh) 抗b7-h3抗体、其抗原结合片段及其医药用途
CA2959171C (fr) Agents de liaison cd123 et leurs utilisations
US20250034248A1 (en) Monoclonal antibodies against human tim-3
US10858442B2 (en) Antibodies that target human CD47
JP2020520655A (ja) 細胞傷害性ｔリンパ球関連タンパク質４（ｃｔｌａ−４）に対する新規モノクローナル抗体
CN105101997A (zh) 不减少血小板和不减少血红细胞的cd47抗体及其使用方法
NZ720161A (en) Production of t cell retargeting hetero-dimeric immunoglobulins
JP2019506844A (ja) ＣＤ３２ｂを標的とする抗体およびその使用方法
CA3119968A1 (fr) Anticorps diriges contre la mucine-16 et leurs procedes d'utilisation
US11643466B2 (en) Humanized anti-PD-L1 antibodies
JP7789304B2 (ja) Ｃｄ４７抗体及びその応用
CA3136450C (fr) Anticorps ciblant la cd47 humaine
US20250297026A1 (en) Therapeutic antibodies
HK40068407A (en) Antibodies that target human cd47
US12286475B2 (en) Anti-GPRC5D antibodies and compositions
HK40068407B (zh) 靶向人cd47的抗体
US20230242646A1 (en) Humanized Anti-Human CD89 Antibodies and Uses Thereof
KR20250059447A (ko) 항-ilt4 항체 및 이의 의약적 용도
HK40068405A (en) Humanized anti-pd-l1 antibodies